Imperial College London

DrAdamByrne

Faculty of MedicineNational Heart & Lung Institute

Lecturer in Chronic Lung Disease
 
 
 
//

Contact

 

a.byrne

 
 
//

Location

 

369Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Byrne:2016:10.1016/j.molmed.2016.02.004,
author = {Byrne, AJ and Maher, TM and Lloyd, CM},
doi = {10.1016/j.molmed.2016.02.004},
journal = {Trends in Molecular Medicine},
pages = {303--316},
title = {Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease?},
url = {http://dx.doi.org/10.1016/j.molmed.2016.02.004},
volume = {22},
year = {2016}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Pulmonary fibrosis (PF) is a growing clinical problem which can result in breathlessness or respiratory failure and has an average life expectancy of 3 years from diagnosis. Therapeutic options for PF are limited and there is therefore a significant unmet clinical need. The recent resurgent interest in macrophage biology has led to a new understanding of lung macrophage origins, biology, and phenotypes. In this review we discuss fibrotic mechanisms and focus on the role of macrophages during fibrotic lung disease. Data from both human and murine studies are reviewed, highlighting novel macrophage-orientated biomarkers for disease diagnosis and potential targets for future anti-fibrotic therapies.
AU - Byrne,AJ
AU - Maher,TM
AU - Lloyd,CM
DO - 10.1016/j.molmed.2016.02.004
EP - 316
PY - 2016///
SN - 1471-4914
SP - 303
TI - Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease?
T2 - Trends in Molecular Medicine
UR - http://dx.doi.org/10.1016/j.molmed.2016.02.004
UR - http://hdl.handle.net/10044/1/32190
VL - 22
ER -